Business
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject enrollment milestone achieved in MIRACLE trial Enrollment in MIRACLE trial continues to advance on pace with 90th subject expected in Q3 2026 HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the firs
About this update from Moleculin Biotech, Inc.
[{"type":"image","alt":"Moleculin Biotech, Inc.","displaySize":"","headline":null,"caption":"Moleculin Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ygVdJytEJhyRWCgJ6Op6NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1OA--/https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3","width":300,"height":113},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ygVdJytEJhyRWCgJ6Op6NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1OA--/https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3","width":300,"height":113}},"lazy":false},{"type":"text","content":"Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial","length":130,"tagName":"p"},{"type":"text","content":"First interim unblinding expected in June 2026 following 45 subject enrollment milestone achieved in MIRACLE trial","length":114,"tagName":"p"},{"type":"text","content":"Enrollment in MIRACLE trial continues to advance on pace with 90th subject expected in Q3 2026","length":94,"tagName":"p"},{"type":"text","content":"HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.","length":222,"tagName":"p"},{"type":"text","content":"“With enrollment now surpassing the first interim analysis threshold in the MIRACLE trial, we are just weeks away from beginning what we believe will be the most transformative period in the Company’s history. The impressive preliminary blinded remission data trend we reported earlier this year continues with the 45 subject blinded data. This trend supports our belief in Annamycin’s potential to meaningfully improve outcomes for patients with relapsed or refractory AML,” said Walter Klemp, Chairman and Chief Executive Officer of Moleculin.","length":545,"tagName":"p"},{"type":"text","content":"“We also believe Annamycin has the potential to redefine the anthracycline class by addressing one of the most significant limitations of these foundational therapies, cardiotoxicity, while potentially expanding access to treatment...